Navigation Links
Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/12/2008

he conference can be obtained at http://www.rodmanandrenshaw.com .

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics is also developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com .

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' prod
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... on Company,s Website -, TUSTIN, Calif., Feb. 7 ... stage biopharmaceutical,company developing monoclonal antibodies for the treatment of ... management will,present at the 10th Annual BIO CEO & ... EST. The conference will be held at the,Waldorf-Astoria Hotel ...
... MAUI, Hawaii, Feb. 7 Bioponic Phytoceuticals,Inc. ("Bioponic" or ... month of January 2008 increased 40% compared to sales ... record breaking month of sales in January, primarily,from continued ... gaining,market traction for our latest product release, an all-natural ...
... China Shenghuo,Pharmaceutical Holdings, Inc. ("China Shenghuo," "the ... research, development, manufacture, and,marketing of pharmaceutical, nutritional ... of China ("PRC"), today announced it will ... the United States during the,first quarter of ...
Cached Biology Technology:Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 3
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... swamps, sawgrass prairies and subtropical jungles, could the Florida ... oil spill? While current estimates are that little ... the Everglades, this area is a significant national natural ... on seagrasses and mangrove forests in and near the ...
... Service Southern Research Station (SRS) Director Jim Reaves today ... nonnative invasive plants in the South can now request ... of Invasive Plants in Southern Forests." The long-awaited book ... Plants of Southern Forests: A Field Guide for Identification ...
... , Opportunities for in-depth interviews and discussions with ... in Europe and beyond You will hear different aspects ... in Europe, Use of ART data from Europe and ... limitations of pooling ART infant outcome data from different ...
Cached Biology News:Gulf oil spill: NSF funds research on impacts to Florida Everglades 2Forest Service updates free guide to 'Invasive Plants in Southern Forests' 2The European IVF Monitoring Group celebrates its 10-year anniversary 2
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-rat Dipeptidyl Peptidase IV (DPP IV), CD26, Clone 5E8, Monoclonal Antibody...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
... used to detect the appearance of AcNPV ... cells as early as 8-24 hours post-infection. ... Titer Kit, which allows determination of baculovirus ... The FastPlax Antibody can also be used ...
Biology Products: